IRVINE, CA--(Marketwire - November 03, 2009) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the world’s leading dental laser company, today announced the launch of the Diolase 10™ Diode Laser for therapeutic applications, including temporary pain relief. The Diolase 10 represents the first product from BIOLASE that is part of a strategic expansion into the medical specialty markets, including sports medicine, orthopedics, physical therapy and chiropractics. The Company will initially focus on the chiropractic market. According to recent industry reports, there are more than 60,000 chiropractors in the United States.
BIOLASE Chief Executive Officer David M. Mulder said, “Chiropractors use new technologies as a primary differentiator for their practices and there is a rapidly growing awareness of successful outcomes with laser treatments in the field. We believe they will see our Diolase 10 as a major new source of revenue outside of insurance reimbursement, which has been dropping steadily over the past few years. The risk of entry into this market for us is low since many components are shared with our ezlase™ platform and many of our experienced ezlase dentists around the world have already been using the laser successfully for dental patients to relieve chronic and acute pain.”
Mulder said the Diolase 10 demonstrates the significant value and broad potential of the BIOLASE laser intellectual property portfolio and added, “While dentistry remains our core thrust, a key part of our growth strategy is to continue to broaden the use of our laser products to a variety of health care and therapeutic markets outside of dentistry. The Diolase 10 is an important example of that effort. BIOLASE is also well versed in establishing relationships with industry leading practitioners, and the technology platform for Diolase 10 and ezlase is being used by leaders in the dentistry and pain management fields for a wide range of patients.”
BIOLASE received FDA clearance in April 2009 to market its diode laser systems with the patented Body Contour™ handpiece for therapeutic applications including pain management. Specific indications that would benefit a chiropractic market include: topical heating for the purpose of elevating tissue temperature for a temporary relief of minor muscle and joint pain and stiffness, minor arthritis pain, or muscle spasm, minor sprains and strains, and minor muscular back pain; the temporary increase in local blood circulation; the temporary relaxation of muscle.
The Diolase 10 carries forward many of the cosmetic and state-of-the-art technological attributes BIOLASE has incorporated into its other lasers, including an award-winning ergonomic design, an intuitive graphic user interface adapted for pain management practitioners, procedure specific presets, battery power, Comfort Pulse and a wireless technology. The new 10 Watt unit has been engineered for the needs of the pain management market and is being introduced with a patented, Body Contour handpiece. Benefits of the new handpiece include a uniform laser energy distribution pattern, adaptation to the body’s anatomical structures and individual disposable infection shields.
For more information on the newly released Diolase 10, contact BIOLASE at 1-877-670-4767. The Diolase 10 is also being previewed today to investors at the 39th annual TechAmerica AeA Classic Financial Conference in San Diego, California.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology, pain management and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300
